Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

674 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Murayama M, et al. Among authors: hirasawa y. Sci Rep. 2024 May 17;14(1):11325. doi: 10.1038/s41598-024-59677-1. Sci Rep. 2024. PMID: 38760458 Free PMC article.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling.
Nakajima Y, Tsuboi N, Katori K, Waili M, Nugroho AE, Takahashi K, Nishino H, Hirasawa Y, Kawasaki Y, Goda Y, Kaneda T, Morita H. Nakajima Y, et al. Among authors: hirasawa y. J Nat Med. 2024 Jun;78(3):568-575. doi: 10.1007/s11418-024-01798-y. Epub 2024 Apr 2. J Nat Med. 2024. PMID: 38564154
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hirasawa y. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.
Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, Yamashita T, Motegi K, Saito A, Kohmoto M, Hosonuma M, Kuramasu A, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Horiike A, Goto S, Murakami M, Kim YG, Tsunoda T, Yoshimura K. Otsuka K, et al. Among authors: hirasawa y. Cancer Immunol Immunother. 2024 Jan 27;73(2):23. doi: 10.1007/s00262-023-03608-y. Cancer Immunol Immunother. 2024. PMID: 38280026 Free PMC article.
674 results